{"DataElement":{"publicId":"2682005","version":"2","preferredName":"Toxicity Alteration Treatment Regimen  Plan Administration Velafermin Therapeutic Procedure Indicator","preferredDefinition":"The indicator that describes whether or not toxicity modifying regimen velafermin was planned to be administered.","longName":"REG_PLN_ADMN_VEL_IND","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2682003","version":"1","preferredName":"Toxicity Alteration Treatment Regimen  Plan Administration Velafermin","preferredDefinition":"The finding of bodily harm due to the poisonous effects of something._A change resulting in something that is different from the original._A treatment plan that specifies the dosage, the schedule, and the duration of treatment._Have a beginning, in a temporal, spatial, or evaluative sense; the point in space or time where something begins._To devise, contrive, or formed in design._The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine._A recombinant human fibroblast growth factor-20 (rhFGF-20) protein with pro-proliferative activity.  Velafermin stimulates DNA synthesis and cell proliferation, specifically promoting epithelial and mesenchymal cell proliferation, and may prevent radiation or chemotherapy-induced oral mucositis.","longName":"REG_PLN_ADMN_VEL","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2692253","version":"1","preferredName":"Toxicity Alteration Regimen","preferredDefinition":"Toxicity; the degree to which something is poisonous.:A change resulting in something that is different from the original.:A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","longName":"C27990:C28344:C15697","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Toxicity","conceptCode":"C27990","definition":"The finding of bodily harm due to the poisonous effects of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Alteration","conceptCode":"C28344","definition":"The act or process of modifying something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3DB49DBC-B4D2-2058-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-30","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-30","modifiedBy":"ONEDATA","dateModified":"2007-10-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2692254","version":"1","preferredName":"Planned Administration Velafermin","preferredDefinition":"Planned; devised, contrived, or formed in design.:The act of administration.:A recombinant human fibroblast growth factor-20 (rhFGF-20) protein with pro-proliferative activity.  Velafermin stimulates DNA synthesis and cell proliferation, specifically promoting epithelial and mesenchymal cell proliferation, and may prevent radiation or chemotherapy-induced oral mucositis.","longName":"C25619:C25409:C48425","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plan","conceptCode":"C25619","definition":"To devise, contrive, or form in design.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Administration","conceptCode":"C25409","definition":"The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Velafermin","conceptCode":"C48425","definition":"A recombinant human fibroblast growth factor-20 (rhFGF-20) protein with pro-proliferative activity.  Velafermin stimulates DNA synthesis and cell proliferation, specifically promoting epithelial and mesenchymal cell proliferation, and may prevent radiation or chemotherapy-induced oral mucositis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3DB49DBC-B4E4-2058-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-30","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-30","modifiedBy":"ONEDATA","dateModified":"2007-10-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A198464-C78E-66D0-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-14","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-14","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2677817","version":"1.1","preferredName":"Therapeutic Procedure Indicator","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether or not certain stated circumstances exist or criteria are satisfied.","longName":"THER_IND","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No: C49487","ValueMeaning":{"publicId":"2577728","version":"1","preferredName":"No: C49487","longName":"2577728","preferredDefinition":"The non-affirmative response to a question.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCAD-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-17","endDate":null,"createdBy":"FRAZIERP","dateCreated":"2006-02-17","modifiedBy":"REEVESD","dateModified":"2006-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"580921B0-775D-4402-E044-0003BA3F9857","beginDate":"2007-09-05","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-09-29","modifiedBy":"ONEDATA","dateModified":"2008-09-29","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"2575365","version":"1","preferredName":"Unknown","longName":"2575365","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F372-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-15","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"MMADDINENI","dateModified":"2024-01-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"580921B0-7771-4402-E044-0003BA3F9857","beginDate":"2007-09-05","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-09-29","modifiedBy":"ONEDATA","dateModified":"2008-09-29","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"2567168","version":"1","preferredName":"Yes","longName":"2567168","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D36D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":"12/29/2006 - Updated with NCI Thesaurus definition.","administrativeNotes":"2022.12.29 Alt VM added per ticket request CADSR0001837. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"580921B0-777B-4402-E044-0003BA3F9857","beginDate":"2007-09-05","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-09-29","modifiedBy":"ONEDATA","dateModified":"2008-09-29","deletedIndicator":"No"},{"value":"Masked trial","valueDescription":"Blinded Clinical Study","ValueMeaning":{"publicId":"2789519","version":"1","preferredName":"Blinded Clinical Study","longName":"2789519","preferredDefinition":"A clinical study that is designed using a procedure in which one or more parties to the study [subject(s), investigator(s), monitor, or/and data analyst(s)] are kept unaware of the treatment assignment(s).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Blinded Clinical Study","conceptCode":"C70840","definition":"A clinical study that is designed using a procedure in which one or more parties to the study [subject(s), investigator(s), monitor, or/and data analyst(s)] are kept unaware of the treatment assignment(s).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"580921B0-77A0-4402-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-09-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"580921B0-77B9-4402-E044-0003BA3F9857","beginDate":"2008-09-29","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-09-29","modifiedBy":"ALEYR","dateModified":"2008-09-29","deletedIndicator":"No"},{"value":"Clinical trial","valueDescription":"Clinical Trial","ValueMeaning":{"publicId":"2677818","version":"1","preferredName":"Clinical Trial","longName":"2677818","preferredDefinition":"A type of research study that tests how well new medical treatments or other interventions work in people.  Such studies test new methods of screening, prevention, diagnosis, or treatment of a disease.  The study may be carried out in a clinic or other medical facility.  Also called a clinical study.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Trial","conceptCode":"C15207","definition":"A type of research study that tests how well new medical treatments or other interventions work in people.  Such studies test new methods of screening, prevention, diagnosis, or treatment of a disease.  The study may be carried out in a clinic or other medical facility.  Also called a clinical study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3969F82A-869D-2904-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-05","endDate":null,"createdBy":"JOSHUAT","dateCreated":"2007-09-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"580921B0-77CE-4402-E044-0003BA3F9857","beginDate":"2007-09-05","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-09-29","modifiedBy":"ALEYR","dateModified":"2008-09-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2684697","version":"1","preferredName":"Therapeutic Procedure Indicator","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.:An event, entity or condition that typically characterizes a prescribed environment or situation. Indicators determine or aid in determining whether or not certain stated circumstances exist or criteria are satisfied. (On-line Medical Dictionary)","longName":"C49236:C25180","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3AFC3669-5350-24B8-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-25","endDate":null,"createdBy":"JOSHUAT","dateCreated":"2007-09-25","modifiedBy":"ONEDATA","dateModified":"2007-09-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"580921B0-7745-4402-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-05","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-09-29","modifiedBy":"MAESKEB","dateModified":"2011-11-11","changeDescription":"09-29-08: Changed the value meaning of the permissible \"masked trial\" to \"blinded clinical study\" (C70840 ). Increased the max length to 60. Deleted the minimum length - RA","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2842912","version":"1","longName":"Therapy","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2842913","version":"1","longName":"Best Response","context":"NHLBI"},{"publicId":"2842917","version":"1","longName":"Supportive","context":"NHLBI"},{"publicId":"2865266","version":"1","longName":"Drug","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"pre_ted_post_fgf_yn","type":"NMDP_FN","context":"NHLBI"},{"name":"PerformedObservationResult:value","type":"HCT_BRIDG","context":"NHLBI"}],"ReferenceDocuments":[{"name":"As part of a toxicity modifyi","type":"Preferred Question Text","description":"As part of a toxicity modifying regimen, was FGF (velafermin) started or is there a plan to use it?","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:2682005","type":"BRIDG Mapping Path","description":"PerformedObservation > PerformedObservationResult.value(ANY=>BL) WHERE PerformedObservation > DefinedObservation.nameCode = \"Start Administration or Plan velafermin\" AND DefinedObservation > DefinedSubstanceAdministration [focal context] > Product > MaterialName.name = \"Velafermin\"","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"580941B3-1BB7-4ABE-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-14","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-09-29","modifiedBy":"KUMMEROA","dateModified":"2021-06-03","changeDescription":"2021-6-3 ak System generated def displayed as alt def. 09-29-08: Updated to used VD 2677817 version 1.1 - RA","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}